pan-serotype dengue virus NS4B inhibitor

oral preclin. candidate, trial planned

From 1.5M cmpd phenotypic screen + opt.

Sci. Transl. Med., Feb. 3, 2021

Novartis (NITD), Emeryville, CA

NITD-688

14. The Novartis pan-serotype dengue virus (DENV) NS4B protein inhibitor, NITD-688, is a preclinical candidate with strong activity against all four serotypes of DENV in vitro and excellent oral…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: